
To evaluate the impact of one‐third‐dose (1/3D) bacillus Calmette‐Guérin (BCG) on oncological outcomes in a large cohort of patients with non‐muscle‐invasive bladder cancer (NMIBC) treated with adequate BCG (as defined by the US Food & Drug Administration (FDA)) in a real‐world setting. We performed an institutional review board‐approved review of patients with NMIBC treated with adequate BCG at our institution between 2000 and 2020. Patients were stratified according to whether they had received 1/3D BCG or full‐dose (FD) BCG. Time to recurrence, time to progression and cancer‐specific survival were estimated using Kaplan–Meier methods...
Like
Save
Share